KYMR

SEC source: 0000899243-20-023368 · doc4.xml · derivative · entry 4

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,388,990 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023368 · doc4.xml · derivative · entry 3

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,880,995 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023368 · doc4.xml · nonDerivative · entry 2

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,112,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering.

F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Dr. Booth is a member of AVAO LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023368 · doc4.xml · nonDerivative · entry 1

Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner

Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner

ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner

Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner

Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner

Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,948,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering.

F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023367 · doc4.xml · derivative · entry 6

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,112,686 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Dr. Booth is a member of AVAO LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023367 · doc4.xml · derivative · entry 5

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 926,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023367 · doc4.xml · derivative · entry 4

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 4,388,990 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023367 · doc4.xml · derivative · entry 3

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,880,995 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023367 · doc4.xml · nonDerivative · entry 2

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,112,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering.

F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Dr. Booth is a member of AVAO LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023367 · doc4.xml · nonDerivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,948,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering.

F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023500 · doc4.xml · derivative · entry 2

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 959,211 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date.

SEC source: 0000899243-20-023500 · doc4.xml · nonDerivative · entry 1

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. · CIK 0001787092 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 959,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · derivative · entry 10

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.0001 par value · 113,290 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · derivative.exercise_price: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F7 · derivative.exercise_date: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F7 · derivative.expiration_date: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · derivative · entry 9

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.0001 par value · 627,598 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · derivative.exercise_price: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F7 · derivative.exercise_date: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F7 · derivative.expiration_date: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · derivative · entry 8

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.0001 par value · 837,916 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · derivative.exercise_price: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F7 · derivative.exercise_date: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F7 · derivative.expiration_date: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · nonDerivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,081

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · nonDerivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,290

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · price: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · nonDerivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,017,307

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 627,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · price: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,359,109

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 837,916

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · price: Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series C Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converted on a one-for-1.5949 basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000899243-20-023241 · doc4.xml · derivative · entry 1

Chesworth Richard · CIK 0001821188 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 351,119

Underlying: Common Stock · 351,119 shares

Expires 2030-08-19

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter.

SEC source: 0000899243-20-023237 · doc4.xml · derivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,399

Underlying: Common Stock · 125,399 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal monthly installments over four (4) years commencing on the date of the Registration Statement Effectiveness.

SEC source: 0000899243-20-023247 · doc4.xml · derivative · entry 1

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,942

Underlying: Common Stock · 48,942 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal monthly installments over four (4) years commencing on the date of the Registration Statement Effectiveness.

SEC source: 0000899243-20-023246 · doc4.xml · derivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of this pecuniary interest therein, if any.

SEC source: 0000899243-20-023242 · doc4.xml · derivative · entry 1

Nicholson Donald William · CIK 0001814617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness.

SEC source: 0000899243-20-023238 · doc4.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness.

SEC source: 0000899243-20-023235 · doc4.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness.

F2 · ownership.direct: The reporting person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-023234 · doc4.xml · derivative · entry 1

Hall Steven Edward · CIK 0001602732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness.

SEC source: 0000899243-20-023227 · doc4.xml · derivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,904

Underlying: Common Stock · 32,904 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal monthly installments over four (4) years commencing on the date of the Registration Statement Effectiveness.

SEC source: 0000899243-20-023230 · doc4.xml · derivative · entry 1

Hedin Andrew · CIK 0001821049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness.

F2 · ownership.direct: The Reporting Person has agreed to assign to Deer Management Co. LLC the right to any shares issuable pursuant to the grant or any proceeds from the sale thereof.

SEC source: 0000899243-20-023228 · doc4.xml · derivative · entry 1

Horobin Joanna · CIK 0001560959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,127

Underlying: Common Stock · 40,127 shares

Expires 2030-08-19

F1 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness.

SEC source: 0001193805-20-001075 · e619891_4-kymr.xml · derivative · entry 7

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 40,127

Underlying: Common Stock, $0.0001 par value · 40,127 shares

Expires not disclosed

F6 · security: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F5 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness.

F6 · derivative.expiration_date: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F6 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F6 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.